75,265 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 75,265 shares of the company’s stock, valued at approximately $3,820,000. The Manufacturers Life Insurance Company owned 0.10% of Enliven Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in ELVN. Spruce Street Capital LP acquired a new stake in shares of Enliven Therapeutics during the second quarter worth $16,697,055. Algert Global LLC acquired a new position in Enliven Therapeutics in the second quarter valued at $3,659,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Enliven Therapeutics in the second quarter valued at $8,165,000. BlackRock Inc. purchased a new position in Enliven Therapeutics during the second quarter worth about $221,255,000. Finally, Deutsche Bank AG purchased a new position in Enliven Therapeutics during the second quarter worth about $2,289,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

ELVN has been the subject of several recent analyst reports. Guggenheim lowered their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. HC Wainwright boosted their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Mizuho upped their price target on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Finally, William Blair started coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating on the stock. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the sale, the chief financial officer owned 40,036 shares in the company, valued at $2,345,308.88. The trade was a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the sale, the director directly owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 196,849 shares of company stock worth $11,344,257. Corporate insiders own 3.00% of the company’s stock.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $57.86 on Wednesday. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32. The business has a 50-day moving average of $55.04 and a 200-day moving average of $43.62. The company has a market capitalization of $4.24 billion, a PE ratio of -34.65 and a beta of 0.30.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.